Recent 8-K filings for COAG

• August 11, 2026, 7:11 AM ET earnings materiality 0.80 positive item 2.02item 9.01

  Hemab Q2 net loss $24.2M; FDA clears sutacimig Phase 3 in Glanzmann thrombasthenia

  Net loss $24.2M ($0.80/share) vs $12.2M ($12.91/share) YoY; cash $457.5M, runway into 2029.

• May 21, 2026, 7:05 AM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases

  Hemab reports Q1 net loss $22.7M; completes $346.7M IPO, gets BTD for sutacimig

  Net loss Q1 2026: $22.7M ($23.98/share) vs $15.3M ($16.18/share) YoY.

• May 11, 2026, 4:01 PM ET leadership materiality 0.20 neutral item 5.02 ◈ executive_change

  Director Laura Tadvalkar resigns from Hemab Therapeutics board effective May 8, 2026

  Laura Tadvalkar, Ph.D., resigned as a member of the Board, effective May 8, 2026.

• May 4, 2026, 7:59 PM ET other material materiality 0.85 positive item 5.03item 8.01item 9.01 ◈ Governance Changes ×2

  Hemab Therapeutics completes IPO of 19.3M shares at $18.00, raising $346.7M

  IPO of 19,262,500 shares at $18.00 per share, including full exercise of underwriter option for 2,512,500 shares.

Executive changes

Materiality & sentiment trend

Max materiality 0.85 · Median 0.80 · Most common event earnings

3 positive 0 negative 1 neutral

source · COAG on sec.gov